BillionToOne (BLLN) Following Q3 Results And The Narrative Behind Its Valuation

BillionToOne (BLLN) drew fresh attention on 4 November 2026 after releasing third quarter results, highlighting US$122.98 million in sales and US$17.39 million in net income from continuing operations.

The recent third quarter release plugged straight into BillionToOne’s share price story, with the stock now at US$113.94 and a 30 day share price return of 19.0% supporting a 27.61% year to date gain. The 1 year total shareholder return of 13.91% points to momentum that has picked up more recently than over the longer stretch.

Scan BillionToOne’s earnings surprise against a hand-picked group of healthcare peers by reviewing the 35 healthcare AI stocks that are also riding clinical and diagnostics momentum.

BillionToOne now trades close to US$114 while analyst targets and intrinsic value estimates point higher, leaving a clear gap on the table. How much of that spread still looks realistic after this latest surge?

Most Popular Narrative: 11% Undervalued

BillionToOne’s most followed valuation story pegs fair value at $128.57, which sits ahead of the latest $113.94 close and frames today’s rally as only part of the gap being addressed.

Growing adoption of noninvasive prenatal testing and broader carrier screening, supported by UNITY publications and an exclusive Johnson & Johnson companion diagnostic agreement, can support higher test volumes and ASPs. This would feed directly into revenue and gross margin.

See why 3 investors see BillionToOne as 11% undervalued.

Result: Fair Value of $128.57 (UNDERVALUED)

Still, BillionToOne’s reliance on prenatal reimbursement and potential margin pressure from a greater oncology mix could both work against that 11% undervalued narrative.

Find out about the key risks to this BillionToOne narrative.

Another View: BillionToOne Looks Expensive On Earnings

The DCF narrative paints BillionToOne as undervalued, yet the earnings multiple tells a tighter story. The stock trades on a P/E of 117x, while the fair ratio sits at 46.3x and the US Healthcare sector averages 24.9x, with peers near 38.6x. That gap points to real valuation risk if expectations reset.

For a closer look at how these earnings based signals stack up against price, See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Mixed messages on BillionToOne’s value story can create noise, so move quickly, review the underlying data, and focus on the 3 key rewards.

Looking For More Ideas Beyond BillionToOne?

If BillionToOne has sharpened your focus, do not stop here. Fresh opportunities emerge constantly, and a few minutes with the right tools can reshape your watchlist.

• Target stability first and hunt for resilient businesses through the 29 resilient stocks with low risk scores that can help anchor a volatile portfolio.
• Spot potential mispricing quickly by checking the 39 high quality undervalued stocks for companies that pair healthy fundamentals with pricing that still looks reasonable.
• Balance growth stories with financial strength and scan the list of solid balance sheet and fundamentals (24 results) to find firms with cleaner debt profiles and sturdier cash positions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com